Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Suspected Herbal Injection Complies With National Standards

This article was originally published in PharmAsia News

Executive Summary

According to Shanxi FDA, Shanxi Taihang Pharmaceutical-produced Yinzhihuang herbal medicine has been examined and proven to comply with China's national drug standards. The herbal medicine caused adverse reactions in four newborn babies in October 2008, resulting in one death (PharmAsia News, Oct. 27, 2008). Subsequently, experts appointed by the state and provincial FDA inspected the company's GMP implementation. In addition, the National Institute for the Control of Pharmaceutical and Biological Products and Shanxi Institute for Drug Control each tested the suspected batch and the results conformed to the national standards. A Shanxi Taihang insider says the company has announced the testing report on its website but resumption ofYinzhihuang sales will depend on the decision of the authorities. (Click here for more - Chinese Language)

You may also be interested in...

China To Review Use Of Chinese Herbal Injections

China's Ministry of Health has held an emergency videoconference to announce the adverse reactions of four newborn babies who were injected with Yinzhihuang herbal medicine. The drug produced by Shanxi Taihang Pharmaceutical has caused one death and the authorities are calling for an immediate recall. From Yuxingcao and Ciwujia to Yinzihuang, controversy and drug safety incidents have been plaguing Chinese herbal injections since they emerged as a new profit stream in the pharmaceutical industry. Experts note that to ensure such products' safety and quality, China's State FDA issued basic technical requirements for traditional Chinese medicine and natural medicine injections last December but the regulations have not been fully implemented. To prevent further incidents, the government should expand more clinical trial coverage and establish an effective adverse drug reaction reporting system. (Click here for more - Chinese Language)

Filgotinib On Uncertain Path As Gilead Regains Speed From Pandemic Hit

Third quarter earnings show Gilead’s Immunomedics buy paid off, but filgotinib’s path may narrow. The HIV and HCV franchises picked up from their COVID-19 lull.

Google Teams Up With Mayo Clinic To Explore AI To Improve Radiotherapy Planning

Mayo Clinic announces AI-based partnerships with Google and voice-analysis company Vocalis Health this week.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts